MedPath

McGuff Pharmaceuticals Receives FDA Approval for Santa Ana Manufacturing Facility

• McGuff Pharmaceuticals, Inc. (MPI) has secured FDA approval for its 86,000-sq.-ft. sterile fill-and-finish pharmaceutical manufacturing plant in Santa Ana, CA. • The approval allows MPI to expand its capabilities as a CMO/CDMO, offering end-to-end drug development and manufacturing services to pharmaceutical companies. • MPI plans to increase production of its Ascorbic Acid Injection (ASCOR) to meet growing national and international demand following the facility's approval. • The new facility will handle NDA and ANDA labeled injectable products, contract manufactured products, and clinical trial products, including sterile and hazardous drugs.

McGuff Pharmaceuticals, Inc. (MPI) has announced FDA approval of its state-of-the-art, 86,000-sq.-ft. sterile fill-and-finish pharmaceutical manufacturing plant in Santa Ana, CA. This approval marks a significant milestone for the company, opening new avenues in both the Contract Manufacturing Organization (CMO) and Contract Development and Manufacturing Organization (CDMO) sectors.

Expanding Manufacturing Capabilities

As a CMO/CDMO, MPI supports pharmaceutical companies in bringing new products and formulations to market. The company offers fully integrated drug development and manufacturing services, encompassing formulation development, product stability, regulatory compliance, and clinical trials, all under stringent quality assurance protocols.
The newly approved facility is designed to handle a diverse range of products, including MPI's NDA and ANDA labeled injectable products, contract manufactured products, and clinical trial materials. Its capabilities include sterile fill-and-finish pharmaceutical manufacturing, compounding for solutions, emulsions, and suspensions, and the handling of both sterile and hazardous drugs in vial sizes ranging from 5mL to 100mL. The facility also provides analytical testing and DSCSA-compliant packaging.

Increased Production of Ascorbic Acid Injection

"With this approval, we will increase our production of ASCOR, our FDA-approved Ascorbic Acid Injection (vitamin C injection), ensuring that we meet the growing demands of our customers, both nationally and internationally," stated Ronald M. McGuff, President of MPI. Ascorbic acid injection is commonly used to treat vitamin C deficiency.

Future Outlook

The FDA approval represents a pivotal moment for MPI, enhancing its ability to serve the pharmaceutical industry with comprehensive manufacturing solutions. The company is poised to leverage its expanded capabilities to meet the increasing demand for sterile injectable products and support the development of new therapies.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Endo Receives FDA Approval for Manufacturing Facility in Indore, India

The U.S. Food and Drug Administration (FDA) has approved Endo's manufacturing facility in Indore, India, for commercial production of VASOSTRICT.
The 20,000-square-foot facility will increase Endo's sterile injectable production capacity and support the growth of its Injectable Solutions business.

Intra-Cellular Therapies Seeks FDA Approval for Caplyta as Adjunctive MDD Treatment

Intra-Cellular Therapies has submitted an sNDA to the FDA for Caplyta (lumateperone) as an adjunctive treatment for major depressive disorder (MDD).
The sNDA is supported by positive Phase 3 results, demonstrating significant antidepressant efficacy and a favorable safety profile for Caplyta.

McGuff Pharmaceuticals Receives FDA Approval for Santa Ana Manufacturing Facility

McGuff Pharmaceuticals, Inc. (MPI) has secured FDA approval for its state-of-the-art, 86,000-sq.-ft. sterile fill-and-finish pharmaceutical manufacturing plant in Santa Ana, CA.
The FDA approval allows MPI to expand its capabilities as a CMO/CDMO, offering integrated drug development and manufacturing services to pharmaceutical companies.

McGuff Pharmaceuticals Receives FDA Approval for Santa Ana Manufacturing Facility

McGuff Pharmaceuticals, Inc. (MPI) has secured FDA approval for its state-of-the-art, 86,000-sq.-ft. sterile fill-and-finish pharmaceutical manufacturing plant in Santa Ana, CA.
The FDA approval allows MPI to expand its capabilities as a CMO/CDMO, offering integrated drug development and manufacturing services to pharmaceutical companies.

STGen Bio's Songdo Plant Secures FDA cGMP Approval, Expanding Global Reach

STGen Bio's Songdo Bio Plant received cGMP approval from the U.S. FDA for its drug substance and pre-filled syringe manufacturing facilities.
This FDA approval, following EMA certification, enables STGen Bio to supply high-quality biopharmaceuticals to the U.S., Europe, and Japan.

SpineGuard's PsiFGuard Receives FDA Clearance for Sacroiliac Joint Fusion

SpineGuard's PsiFGuard, a smart drilling device for posterior sacroiliac fusion (PsiF), has received FDA 510(k) clearance for commercial use in the United States.
The PsiFGuard device utilizes SpineGuard's Dynamic Surgical Guidance (DSG®) technology to enhance the accuracy of implant placement in SI joint fusion procedures.

Establishment Labs Gains FDA Approval for Motiva Breast Implants

Establishment Labs has received FDA approval for its Motiva SmoothSilk Ergonomix and Round breast implants for primary and revision augmentation.
The Motiva implants feature a patented SmoothSilk surface, designed to enhance biocompatibility and promote low inflammation.

GC Biopharma and Hanmi Pharmaceutical's Fabry Disease Treatment LA-GLA Receives FDA IND Clearance

GC Biopharma and Hanmi Pharmaceutical received FDA IND clearance for Phase 1/2 clinical trial of LA-GLA (GC1134A/HM15421), a novel Fabry disease treatment.
LA-GLA is designed as a once-monthly subcutaneous injection, offering improved convenience compared to current bi-weekly intravenous enzyme replacement therapies.

FDA Clears IND for Myogenica's MyoPAXon in Duchenne Muscular Dystrophy

Myogenica, a University of Minnesota startup, received FDA clearance for its IND application for MyoPAXon, a stem cell therapy for muscular regeneration.
The planned clinical trial will assess the safety, tolerability, and engraftment of MyoPAXon in adult patients with Duchenne muscular dystrophy (DMD).

FDA Approves Santhera's Agamree (Vamorolone) for Duchenne Muscular Dystrophy

The FDA has approved Agamree (vamorolone) for treating Duchenne Muscular Dystrophy (DMD) in patients aged two years and older, offering a novel corticosteroid treatment option.
Agamree demonstrated comparable efficacy to standard corticosteroids in clinical trials, with data suggesting a reduction in adverse events related to bone health, growth, and behavior.

Reference News

[1]
FDA Approves McGuff Pharmaceuticals Facility In Santa Ana, CA | Contract Pharma
contractpharma.com · Oct 31, 2024

McGuff Pharmaceuticals, Inc. (MPI) received FDA approval for its 86,000-sq.-ft. sterile fill-and-finish facility in Sant...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy